Clinical Trials on Neuroendocrine Tumors (NET) in Finland

Total 428 results

National Cancer Institute (NCI)

Active, not recruiting

Octreotide Acetate and Recombinant Interferon Alfa-2b or Bevacizumab in Treating Patients With Metastatic or Locally Advanced, High-Risk Neuroendocrine Tumor

Neuroendocrine Tumor | Neuroendocrine Neoplasm | Colorectal Neuroendocrine Tumor G1 | Gastric Neuroendocrine Tumor G1 | Neuroendocrine Tumor G2

United States
Turku University Hospital
Helsinki University Central Hospital

Unknown

Nonfunctional Pancreatic NET and PET Imaging

Diagnosis

Finland
National Cancer Institute (NCI)

Active, not recruiting

Testing Cabozantinib in Patients With Advanced Pancreatic Neuroendocrine and Carcinoid Tumors

Carcinoid Tumor | Functioning Pancreatic Neuroendocrine Tumor | Intermediate Grade Lung Neuroendocrine Neoplasm | Locally Advanced Pancreatic Neuroendocrine Tumor | Locally Advanced Unresectable Digestive System Neuroendocrine Neoplasm | Low Grade Lung Neuroendocrine Neoplasm | Metastatic Digestive... and other conditions

United States
University of Turku

Completed

Bevacizumab, Dacarbazine and Interferon-Alfa to Treat Metastatic Melanoma

Metastatic Melanoma

Finland
Ipsen

Completed

Study For Evaluating The Value Of A Multi Biomarker Approach In Metastatic GEP NETs (EXPLAIN)

Gastroenteropancreatic Neuroendocrine Tumors

Finland, Norway, Sweden, Denmark, Latvia, Lithuania, Estonia
National Cancer Institute (NCI)

Completed

Everolimus and Octreotide Acetate With or Without Bevacizumab in Treating Patients With Locally Advanced or Metastatic Pancreatic Neuroendocrine Tumors That Cannot Be Removed by Surgery

Locally Advanced Pancreatic Neuroendocrine Tumor | Pancreatic Neuroendocrine Tumor G1 | Pancreatic Neuroendocrine Tumor G2 | Pancreatic Vipoma | Pancreatic Gastrinoma | Advanced Pancreatic Neuroendocrine Tumor

United States, Canada
SWOG Cancer Research Network
National Cancer Institute (NCI)

Recruiting

Testing the Use of Chemotherapy After Surgery for High-Risk Pancreatic Neuroendocrine Tumors

Pancreatic Neuroendocrine Tumor | Metastatic Malignant Neoplasm in the Liver | Stage I Pancreatic Neuroendocrine Tumor AJCC v8 | Stage II Pancreatic Neuroendocrine Tumor AJCC v8 | Stage III Pancreatic Neuroendocrine Tumor AJCC v8

United States
University Hospital, Tours
European Academy of Dermatology and Venerology

Not yet recruiting

SerUM Markers in MERkel Cell Carcinoma Patients: a Longitudinal moniTorIng Study for optiMization of European Guidelines (SUMMERTIME)

Merkel Cell Carcinoma

United Kingdom, Austria, Finland, France, Germany, Italy, Netherlands, Romania, Sweden, Turkey
National Cancer Institute (NCI)

Completed

Sapanisertib in Treating Patients With Metastatic or Refractory Pancreatic Neuroendocrine Tumor That Cannot Be Removed by Surgery

Refractory Pancreatic Neuroendocrine Carcinoma | Pancreatic Neuroendocrine Tumor G1 | Pancreatic Neuroendocrine Tumor G2

United States
Joint Authority for Päijät-Häme Social and Health...
Tampere University; Huslab, Finland

Completed

Photodynamic Therapy for Lentigo Maligna Using 5-aminolevulinic Acid Nanoemulsion as a Light Sensitizing Cream (LM PDT)

Lentigo Maligna

Finland
Helsinki University Central Hospital

Completed

Nut Allergy Study: Double-blind Challenge and Oral Desensitization

Nut Allergy

Finland
Helsinki University Central Hospital

Completed

The Effect of Per Oral Immunotherapy in Severe IgE Mediated Egg, Milk, and Nut Allergy in Adults

Food Allergy

Finland
Alliance for Clinical Trials in Oncology
National Cancer Institute (NCI)

Recruiting

Comparing Capecitabine and Temozolomide in Combination to Lutetium Lu 177 Dotatate in Patients With Advanced Pancreatic Neuroendocrine Tumors

Metastatic Pancreatic Neuroendocrine Tumor | Unresectable Pancreatic Neuroendocrine Carcinoma

United States
Helsinki University Central Hospital

Active, not recruiting

Negative-pressure Wound Therapy on Full-thickness Skin Grafts of the Lower Leg

Skin Tumor

Finland
Molecular Insight Pharmaceuticals, Inc.

Completed

Phase 1 Study of Iobenguane (MIBG) I 131 in Patients With Malignant Pheochromocytoma/Paraganglioma

Pheochromocytoma | Paraganglioma

United States
Helsinki University Central Hospital
University of Helsinki; Tampere University; Tampere University Hospital; Finnish...

Active, not recruiting

Postmortem Evaluation of Adrenal and Other Endocrine Tumors in Patients With Sudden Death (SuddenDeath)

Primary Aldosteronism | Pheochromocytoma | Adrenal Cushing Syndrome | Endocrine Neoplasia

Finland
Hoffmann-La Roche

Completed

A Study of the Effect of Vemurafenib on the Pharmacokinetics of Phenprocoumon in Patients With BRAFV600 Mutation-Positive Metastatic Malignancy

Malignant Melanoma, Neoplasms

Belgium, Spain, Germany, Netherlands, Finland
National Cancer Institute (NCI)

Recruiting

Evaluating the Addition of the Immunotherapy Drug Atezolizumab to Standard Chemotherapy Treatment for Advanced or Metastatic Neuroendocrine Carcinomas That Originate Outside the Lung

Advanced Extrapulmonary Neuroendocrine Carcinoma | Metastatic Extrapulmonary Neuroendocrine Carcinoma | Recurrent Extrapulmonary Neuroendocrine Carcinoma | Unresectable Extrapulmonary Neuroendocrine Carcinoma

United States
Brown University
The Miriam Hospital; Rhode Island Hospital

Active, not recruiting

Adjuvant Nivolumab & Low Dose Ipilimumab for Stage III & Resected Stage IV Melanoma

Melanoma

United States
Molecular Insight Pharmaceuticals, Inc.

Unknown

A Study Evaluating Ultratrace Iobenguane I131 in Patients With Malignant Relapsed/Refractory Pheochromocytoma/Paraganglioma

Pheochromocytoma | Paraganglioma

United States
TILT Biotherapeutics Ltd.

Recruiting

Oncolytic Adenovirus TILT-123 and Avelumab for Treatment of Solid Tumors Refractory to or Progressing After Anti-PD(L)1 (AVENTIL)

Melanoma | Head and Neck Squamous Cell Carcinoma

United States, Finland
Orion Corporation, Orion Pharma

Completed

ODM-207 in Patients With Advance Solid Tumours (BETIDES)

Solid Tumors

Finland
Vivoxid Ltd

Completed

Bioactive Glass as Bone Graft Substitute in Operative Treatment of Bone - a 10 Years Follow-up Study

Spinal Fusion | Depressed Lateral Condyle Fracture | Benign Bone Tumour Cavity

Finland
Bayer
Amgen

Completed

Treatment for Subjects With Unresectable Stage III or Stage IV Melanoma

Melanoma | Cancer

United States
Hoffmann-La Roche

Completed

A Pharmacokinetic/Pharmacodynamic Study of RO5185426 in Previously Treated Patients With Metastatic Melanoma

Malignant Melanoma

United States, Australia
Bristol-Myers Squibb
Medarex

Completed

A Single Arm Study of Ipilimumab Monotherapy in Patients With Previously Treated Unresectable Stage III or IV Melanoma

Melanoma

United States, Spain, Austria, Italy, Sweden, Russian Federation, Ukraine, Finland, Norway, Poland
ECOG-ACRIN Cancer Research Group
National Cancer Institute (NCI)

Active, not recruiting

Cisplatin, Carboplatin and Etoposide or Temozolomide and Capecitabine in Treating Patients With Neuroendocrine Carcinoma of the Gastrointestinal Tract or Pancreas That Is Metastatic or Cannot Be Removed by Surgery

Gastric Neuroendocrine Carcinoma | Intestinal Neuroendocrine Carcinoma | Pancreatic Neuroendocrine Carcinoma

United States
Children's Oncology Group
National Cancer Institute (NCI)

Completed

Evaluating Dactinomycin and Vincristine in Young Patients With Cancer

Unspecified Childhood Solid Tumor, Protocol Specific | Ewing Sarcoma of Bone | Ewing Sarcoma | Childhood Acute Lymphoblastic Leukemia | Wilms Tumor and Other Childhood Kidney Tumors | Childhood Rhabdomyosarcoma | Childhood Soft Tissue Sarcoma | Ewing Sarcoma/Peripheral Primitive Neuroectodermal Tumor...

United States, Australia, Canada
Eli Lilly and Company

Completed

A Study of Cixutumumab (IMC-A12) in Islet Cell Cancer

Carcinoma | Neuroendocrine Tumors

United States
BioVex Limited
Amgen

Completed

Efficacy and Safety Study of Talimogene Laherparepvec Compared to Granulocyte Macrophage Colony Stimulating Factor (GM-CSF) in Melanoma

Melanoma

United States, United Kingdom, Canada, South Africa
Bristol-Myers Squibb

Completed

Study of Nivolumab (BMS-936558) Compared With Dacarbazine in Untreated, Unresectable, or Metastatic Melanoma (CheckMate 066)

Melanoma

Canada, Australia, Germany, Italy, Poland, France, Denmark, Argentina, Chile, Spain, Norway, Israel, Sweden, Mexico, Greece, Finland
NCIC Clinical Trials Group

Completed

Flavopiridol in Treating Patients With Metastatic Malignant Melanoma

Melanoma (Skin)

Canada
European Organisation for Research and Treatment...

Unknown

Vaccine Therapy in Treating Patients With Primary Stage II Melanoma

Melanoma (Skin)

Italy, France, Spain, Switzerland, United Kingdom, Belgium, Australia, Norway, Poland, Finland, Netherlands, Germany, Israel, Denmark, Serbia, Estonia, Portugal, Russian Federation
Turku University Hospital

Completed

Bioactive Glass Granules in Filling of Bone Defects

Bone Tumors

Finland
Bristol-Myers Squibb

Completed

Nivolumab Combined With Ipilimumab Followed by Nivolumab Monotherapy as First-Line Treatment for Patients With Advanced Melanoma (CheckMate 401)

Melanoma

Australia, France, Italy, Belgium, Finland, Austria, Ireland, Sweden, Switzerland, United Kingdom, Germany, Norway
Ipsen

Terminated

Study to Assess the Efficacy and Safety of Different Doses of BIM 23A760 in Patients With Carcinoid Syndrome (CAMPANULA)

Carcinoid Syndrome

Spain, Belgium, Ireland, Czechia, Israel, France, United Kingdom, Latvia, Germany, Russian Federation, Slovakia, Italy, Netherlands, Finland, Austria, Poland, Sweden, Ukraine
Alliance for Clinical Trials in Oncology
National Cancer Institute (NCI)

Completed

Diagnostic Study to Predict the Risk of Developing Metastatic Cancer in Patients With Stage I or Stage II Melanoma

Melanoma (Skin)

United States
University of Helsinki

Completed

Connection Between Periodontitis and Exudative Age-related Macular Degeneration (FLAREPARO)

Periodontitis

Finland
Bristol-Myers Squibb

Completed

A Single-Arm, Open-Label, Multicenter Clinical Trial With Nivolumab (BMS-936558) for Subjects With Histologically Confirmed Stage III (Unresectable) or Stage IV Melanoma Progressing Post Prior Treatment Containing an Anti-CTLA4 Monoclonal Antibody (CheckMate 172)

Melanoma

Germany, Italy, Sweden, United Kingdom, Belgium, Netherlands, Spain, Finland, Austria, Ireland, Poland, Portugal, Russian Federation, Switzerland, Czechia, Greece, Hungary, Luxembourg, Norway, Romania
Eli Lilly and Company

Terminated

A Study of Tasisulam-sodium Versus Paclitaxel as Treatment for Metastatic Melanoma (SUMMIT-1)

Melanoma

United States, Italy, Australia, Spain, France, Netherlands, United Kingdom, Austria, Poland, Germany, Belgium, Taiwan, Canada, Finland, Israel, Korea, Republic of, Norway, Sweden
Bristol-Myers Squibb

No longer available

Expanded Access Program With Nivolumab in Combination With Ipilimumab in Patients With Tumors Unable to be Removed by Surgery or Metastatic Melanoma (CheckMate218)

Malignant Melanoma

United States, Canada
Amgen
Merck Sharp & Dohme LLC

Terminated

Pembrolizumab With Talimogene Laherparepvec or Placebo in Unresected Melanoma (MASTERKEY-265)

Melanoma

United States, Finland, France, Germany, Italy, Canada, Czechia, Poland, Switzerland, Korea, Republic of, Russian Federation, United Kingdom, Australia, Netherlands, Spain, Austria, Belgium, Hungary, Portugal, Greece, South Africa
Novartis Pharmaceuticals

Completed

Everolimus and Octreotide in Patients With Advanced Carcinoid Tumor (RADIANT-2)

Carcinoid Tumor | Malignant Carcinoid Syndrome

France, Spain, Netherlands, United States, Canada, Sweden, Italy, Australia, Germany, Greece, Belgium, Czech Republic, Slovakia, Finland, United Kingdom
Saint John's Cancer Institute
National Cancer Institute (NCI); National Institutes of Health (NIH)

Completed

Multicenter Selective Lymphadenectomy Trial II (MSLT-II)

Melanoma

United States, Australia, Italy, Spain, Canada, Netherlands, Germany, Finland, Israel, Sweden, Switzerland, United Kingdom
Bristol-Myers Squibb

Active, not recruiting

A Study of Relatlimab Plus Nivolumab Versus Nivolumab Alone in Participants With Advanced Melanoma (RELATIVITY-047)

Melanoma

Italy, United States, Germany, Argentina, Australia, Austria, Belgium, Brazil, Canada, Chile, Colombia, Denmark, Finland, France, Greece, Israel, Mexico, New Zealand, Norway, Poland, Romania, Russian Federation, Spain, Sweden, United Kingdom
Bristol-Myers Squibb
Nektar Therapeutics

Completed

A Study of NKTR-214 Combined With Nivolumab vs Nivolumab Alone in Participants With Previously Untreated Inoperable or Metastatic Melanoma

Melanoma

Canada, Australia, France, Italy, Brazil, United States, Argentina, Austria, Belgium, Chile, Czechia, Finland, Germany, Greece, Ireland, Israel, Mexico, Netherlands, New Zealand, Poland, Portugal, Romania, Russian Federation, Spain, Sweden and more
Rhode Island Hospital
National Cancer Institute (NCI)

Unknown

Computer-Based Continuing Education for Doctors in Examination and Counseling of Patients on Skin Cancer or Weight Control

Melanoma (Skin) | Non-melanomatous Skin Cancer

United States
European Organisation for Research and Treatment...

Unknown

High-Dose or Low-Dose Interferon Alfa Compared With No Further Therapy Following Surgery in Treating Patients With Stage III Melanoma

Melanoma (Skin)

France, Switzerland, Netherlands, Poland, Finland, Belgium, United Kingdom, Austria, Germany, Italy, Israel, Slovakia, Spain, Serbia, Portugal, Russian Federation, Bulgaria, Croatia, Turkey, Estonia, Sweden
Novartis Pharmaceuticals

Completed

Dabrafenib Plus Trametinib vs Vemurafenib Alone in Unresectable or Metastatic BRAF V600E/K Cutaneous Melanoma (COMBI-v)

Melanoma

United States, United Kingdom, Austria, Belgium, Hungary, Canada, Netherlands, Argentina, Australia, Brazil, Czechia, Denmark, France, Germany, Israel, Italy, Norway, Poland, Russian Federation, Spain, Switzerland, Taiwan, Korea, Republic... and more
Bristol-Myers Squibb

Active, not recruiting

A Study to Assess Adjuvant Immunotherapy With Nivolumab Plus Relatlimab Versus Nivolumab Alone After Complete Resection of Stage III-IV Melanoma (RELATIVITY-098)

Melanoma

United States, Italy, Argentina, Australia, Austria, Belgium, Brazil, Canada, Chile, China, Czechia, Denmark, Finland, France, Germany, Greece, Israel, Mexico, Norway, Romania, Spain, Sweden, Switzerland, United Kingdom

Clinical Trials on Neuroendocrine Tumors (NET) in Finland

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Netherlands

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations